Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.56 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | CTSE | P14091 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30955742 | 0.95 | DDB1 (0.52) | DDB1CRBNTNK2KDM5AGPR119 | |
| SCHEMBL30955768 | 0.95 | DDB1 (0.52) | DDB1CRBNTNK2KDM5AGPR119 | |
| SCHEMBL9951885 | 0.95 | DDB1 (0.52) | DDB1CRBNTNK2KDM5AGPR119 | |
| SCHEMBL1703877 | 0.93 | KDM5A (0.53) | DDB1CRBNTNK2KDM5AGPR119 | |
| SCHEMBL1703555 | 0.93 | KDM5A (0.53) | DDB1CRBNTNK2KDM5AGPR119 | |
| SCHEMBL1703557 | 0.93 | KDM5A (0.53) | DDB1CRBNTNK2KDM5AGPR119 | |
| SCHEMBL1703878 | 0.87 | KDM5A (0.44) | DDB1CRBNTNK2KDM5AGPR119 | |
| SCHEMBL17402370 | 0.86 | GPR119 (0.57) | DDB1CRBNTNK2GPR119CCNC | |
| SCHEMBL12121174 | 0.86 | DDB1 (0.57) | DDB1CRBNTNK2GPR119HPGD | |
| SCHEMBL16096491 | 0.86 | DDB1 (0.57) | DDB1CRBNTNK2GPR119HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818749-B | Method for synthesizing On-DNA aryl sulfonamide compounds in construction of DNA coding compound library | 上海药明康德新药开发有限公司 | 2023-04-07 | — | — | CN | claimed |
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260028343-A1 | Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3 | CELGENE CORPORATION (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12516063-B2 | Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives for treating autoimmune diseases | ELI LILLY AND COMPANY (US) | 2026-01-06 | — | — | US | disclosed |
| US-20110160209-A1 | SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. | 2011-06-30 | — | — | US | disclosed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144468-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | DDB1 826/4885CRBN 3196/4885TNK2 220/4885 |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | DDB1 716/4885CRBN 17/4885TNK2 3516/4885 |
| US-20260028343-A1 | Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3 | IRAK3, IRAK2, IRAK1 | DDB1 1089/4885CRBN 35/4885TNK2 1555/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | DDB1 425/4885CRBN 32/4885TNK2 1326/4885 |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | DDB1 4768/4885CRBN 349/4885TNK2 1178/4885 |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBLC, CBL | DDB1 365/4885CRBN 1/4885TNK2 3793/4885 |
| US-20110160209-A1 | SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS | MAP4K2, MAP3K15, MAP3K5 | DDB1 898/4885CRBN 1239/4885TNK2 65/4885 |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | DDB1 435/4885CRBN 486/4885TNK2 151/4885 |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | DDB1 2875/4885CRBN 555/4885TNK2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.